Methods of preparation of N-(3-hydroxy-2-phosphonomethoxypropyl) (HPMP) derivatives of (2S)- and (2R)-configuration (compounds I and XXVII, respectively) are described. The general method starts from the corresponding N-(2,3-dihydroxypropyl) derivatives which were converted either into the (R)-enantiomers XIII by reaction of the base with (R)-glycidol butyrate (XII) in the presence of cesium carbonate and subsequent methanolysis, or into the (S)-enantiomers XI by alkylation of the base with (R)-2,2-dimethyl-4-tosyloxymethyl-1,3-dioxolane (V) in the presence of the same reagent. The amino groups on the heterocyclic base in compounds XI and XIII were benzoylated by silylation followed by reaction with benzoyl chloride and the obtained N-benzoates XV and XVII on reaction with trityl chloride afforded the corresponding 3'-O-trityl derivatives XVI and XVIII. These compounds were condensed with bis(2-propyl) p-sulfonyloxymethylphosphonate (XXIII) in dimethylformamide in the presence of sodium hydride to give the fully protected diesters XXIV and XXVIII. These compounds could be selectively acid-hydrolyzed to remove the trityl group only under formation of compounds XXXV, or methanolyzed and then acid-hydrolyzed to remove the trityl and N-benzoyl groups and lead to compounds XXVI and XXX, or treated with bromotrimethylsilane to remove the trityl and 2-propyl group to give phosphonates of the type XXXI. All the three types of compounds were then converted into free phosphonates of the (S)-series (I) and the (R)-series (XXVII). Derivatives of cytosine (Ia, XXVIIa), adenine (Ib, XXVIIb), 2,6-diaminopurine (Ic, XXVIIc) and guanine (Id, XXVIId) were prepared. Condensation of the partially blocked adenine deriavtive XXXV with the tosyl derivative XXIII and subsequent deprotection afforded 9-(S)-(2,3-diphosphonomethoxy propyl)adenine (XLIII). Reaction of the same compound XXXV or its (R)-enantiomer XXXVIII with diethyl phosphonate , followed by deblocking, afforded 3'-O-phosphoryl derivatives (S)-HPMPA (XXXVII) and (R)-HPMPA (XL).
描述了制备N-(3-羟基-2-膦甲氧基丙基)(HPMP)衍生物的方法,其中包括(2S)-和(2R)-构型的化合物I和XXVII。一般方法始于相应的N-(2,3-二羟基丙基)衍生物,通过将其转化为(R)-对映体XIII(通过碱与(R)-环氧丙酯(XII)在碳酸铯存在下的反应和随后的甲醇解)或通过在相同试剂存在下,通过碱与(R)-2,2-二甲基-4-对甲苯磺酰氧甲基-1,3-二氧兰(V)烷基化,将其转化为(S)-对映体XI。化合物XI和XIII中的杂环碱基上的氨基被硅烷化后与苯甲酰氯反应,得到的N-苯甲酸酯XV和XVII在与三苯甲基氯反应时生成相应的3'-O-三苯甲基衍生物XVI和XVIII。这些化合物与双(2-丙基)对磺酸氧甲基膦酸酯(XXIII)在二甲基甲酰胺中与氢化钠存在下反应,得到完全保护的二酯体XXIV和XXVIII。这些化合物可以选择性地酸水解以去除三苯甲基基团,仅形成化合物XXXV,或者经甲醇解然后酸水解以去除三苯甲基和N-苯甲酰基团,并导致化合物XXVI和XXX,或者经溴三甲基硅烷处理以去除三苯甲基和2-丙基基团,形成XXXI型膦酸酯。然后将这三种类型的化合物转化为(S)-系列(I)和(R)-系列(XXVII)的自由膦酸酯。制备了胞嘧啶(Ia、XXVIIa)、腺嘌呤(Ib、XXVIIb)、2,6-二氨基嘌呤(Ic、XXVIIc)和鸟嘌呤(Id、XXVIId)的衍生物。部分阻塞的腺嘌呤衍生物XXXV与甲磺酰衍生物XXIII进行缩合反应,随后去保护作用,得到9-(S)-(2,3-二磷酸甲氧基丙基)腺嘌呤(XLIII)。将相同化合物XXXV或其(R)-对映体XXXVIII与二乙基膦酸酯反应,随后去保护,得到3'-O-磷酰化衍生物(S)-HPMPA(XXXVII)和(R)-HPMPA(XL)。